Assisting Industry to Develop, Test and Prove Ideas.

Home

money from bracket
COMMERCIALIZE TECHNOLOGY
g1018

With the resources of the SUNY Research Foundation, and our history of successful partnerships, we are here to help move biomedical products and ideas to market.

LEARN MORE
LEARN MORE
radar
ENGAGE WITH AN EXPERT
g1074

Our scientists and core facilities can help move discoveries into practice and technologies into the marketplace.

MEET THE TEAM
MEET THE TEAM
microscope
UTILIZE CORE FACILITIES
g1134

Upstate is home to top research facilities with highly specialized equipment and advanced instrumentation, to support research and product development.

VIEW
VIEW
handshake simple
COLLABORATIVE RESEARCH
Researcher Observing Virus culture

We are here to create the relationships and partnerships needed to move innovative ideas forward.

LET'S GET STARTED
LET'S GET STARTED

Recent Tech from SUNY Upstate

Discovery of Novel SHIP1 Agonists
July 11, 2023

A new class of SHIP1 agonists that offer the potential for the development of new treatments for a v...

A new class of SHIP1 agonists that offer the potential for the development of new treatments for a variety of diseases.  Background:
An agonist is a drug or substance that binds to a cell receptor, producing the same action as the substance that would naturally bind to the receptor. Agonists form the basis for a wide variety of therapeutics. The SH-2 containing inositol 5’ polyphosphatase 1 (SHIP1) is a multifunctional protein expressed predominantly by hematopoietic cells. Over the last decade, SHIP1 has been identified as a therapeutic target due to its role in immune cells. It also plays a role in the survival of certain cancers. For example, a SHIP1-selective inhibitor has been shown to be an effective promoter of immune responses to tumor cells, a chemotherapeutic for Blymphoid cancers, hematopoietic stem cell (HSC) mobilization, and engraftment of autologous and allogeneic HSC in murine models of disease or transplantation.Technology Overview:  
This technology consists of analogs to K306, the most potent SHIP1 agonist identified to date. K306 exhibits selectivity for SHIP1 vs. the paralog enzyme SHIP2; this activation does not require the C2 domain of SHIP1 (which other known SHIP1 agonists require). Thus, K306 represents a new class of SHIP1 agonists with a novel mode of agonism. K306 can also suppress induction of inflammatory cytokines and iNOS in macrophages or microglia, but not by their SHIP1-deficient counterparts. In addition, K306 reduces TNF-α production in vivo in an LPS-induced endotoxemia assay. Finally, K306 enhances phagolysosomal degradation of synaptosomes and dead neurons by microglia, revealing a novel function for SHIP1 that might be exploited therapeutically in dementia. https://suny.technologypublisher.com/files/sites/adobestock_356174772.jpeg Advantages:  
•    Represents a new class of SHIP1 agonists with a novel mode of agonism. 
•    Suppresses induction of inflammatory cytokines and iNOS in macrophages or microglia.
•    Reduces TNF-α production in vivo in an LPS-induced endotoxemia assay. 
•    Offers a potential treatment for dementia. Applications:  
The primary application for this technology is the development of therapeutics based on SHIP1 agonists. Intellectual Property Summary:
Patent application filed on 11/15/22: 63/425,601Stage of Development:
TRL 3 - Experimental proof of concept Licensing Status:
This technology is available for licensing.Licensing Potential: This technology would be of interest to anyone involved in medical research and development, including:
•    Pharmaceutical and healthcare companies.
•    Hospitals.
•    Universities.
•    Medical research laboratories.­

ABI1 Regulates Transcriptional Activity of Androgen Receptor by Novel DNA and AR Binding M…
July 07, 2023

Provides new pathways for biomarkers and drug discovery for cancer patients.  Background: The gene A...

Provides new pathways for biomarkers and drug discovery for cancer patients.  Background:
The gene Abelson interactor protein-1 (ABI1) encodes a member of the Abelson-interactor family of adaptor proteins. These proteins facilitate signal transduction as components of several multiprotein complexes, and regulate actin polymerization and cytoskeletal remodeling through interactions with Abelson tyrosine kinases. The androgen receptor (AR) protein functions as a steroid-hormone activated transcription factor. ABI1 and AR are widely expressed in human tissues. Many cancers show sex-specific tumorigenesis, tumor progression, and sensitivity to hormonal drugs. The ABI1-AR axis might play critical roles in these tissue and drug sensitivities and toxicities. For example, ABI1 regulates a specific subset of genes associated with prostate tumor progression. These genes are biomarkers and potential targets of tumor progression.
Technology Overview:  
This technology defines ABI1-AR reciprocal regulation involving two non-exclusive molecular mechanisms of ABI1-AR and ABI1-DNA interactions. ABI1-DNA binding activity predicts survival of prostate cancer patients. ABI1 binds AR via a multivalent interaction. The ABI1-AR transcriptional program is altered during tumor progression and by anti-androgen treatments, suggesting that ABI1 is a key plasticity regulator in PCa by coupling its actin regulatory and signaling functions to transcriptional regulation. ABI1-AR reciprocal regulation has far reaching implications for tumor plasticity and androgen-sensitive pathogenesis. These interactions are co-regulated during PCa evolution and clinical treatment promoting tumor plasticity and progression. This provides new paths for biomarker and drug design discovery in PCa. https://suny.technologypublisher.com/files/sites/adobestock_282277912.jpegAdvantages:  
•    Provides a novel mechanism for predicting survival rates among cancer patients.
•    May enable drug discovery for a wide variety of cancers. Applications:  
The primary applications for this technology are the development of biomarkers for assessing cancer patient survival rates, and drug discovery.  Intellectual Property Summary: US Provisional Patent Application Ser. No. 63/463,457, filed May 2, 2023. Stage of Development:
TRL 3 - Experimental proof of concept Licensing Status:
This technology is available for licensing.Licensing Potential:
This technology would be of interest to anyone involved in the development of biomarkers and/or therapeutics for cancer, including:
•    Pharmaceutical companies.
•    Hospitals.
•    Medical research laboratories.
•    Universities.

 

Novel Suturing Device Kit
July 11, 2023

A surgical "sewing machine" for rapid graft quilting and suturing in challenging spaces. Background:...

A surgical "sewing machine" for rapid graft quilting and suturing in challenging spaces. Background: Grafts are commonly employed in urologic reconstructive surgery, but anchoring them in less accessible areas -- as in luminal stenosis surgery -- can be difficult. A novel surgical "sewing machine" capable of quilting and suturing in tight spaces was developed to help solve this problem. Technology Overview: The repair of luminal stenosis involves an incision through the stenosed segments and followed by the application of a buccal mucosa graft to serve as protection. A surgical sewing machine was assembled by threading absorbable 4-0 barbed suture through a 20-gauge hollow needle. The result is rapid, one hand suturing for graft quilting, with a running stitch, akin to the way a sewing machine makes a continuous stitch across the hem of a skirt. This suturing device, developed by Upstate Medical University researchers, has been used in posterior urethroplasties, a transvesical bladder neck reconstruction, augmented perineal urethrostomy, and a vaginoplasty revision. In each case, the graft survived and there was no recurrence of disease. Advantages:

  • Higher rate of graft success with no recurrence of disease
  • One handed suturing avoids alternating movements to reposition the needle, and is more efficient
  • Can be used in a variety of complex reconstructive surgeries, including those involving radiated tissue, where graft fixation and suturing is challenging
  • Future applications in endoscopic and laparoscopic surgery are possible
Intellectual Property Summary: Patent filed, 16/604,858, on Suturing Device And Methods Of Use Thereof   Licensing Potential: Licensing, Development partner, Commercial partner Licensing Status: This technology is available for licensing.  Licensing. ID: 110-2026 https://suny.technologypublisher.com/files/sites/110-2026skin_grafting.jpg  

Adapter Couples Self-Retaining Surgical Retractor with Hand-Held Retractors
May 07, 2024

An adapter that expedites bone surgery by making hand-held retractors self-retaining.  Background: O...

An adapter that expedites bone surgery by making hand-held retractors self-retaining.  Background: Orthopedic surgeons require unfettered access to exposed bone. That means keeping the skin, subcutaneous fat, tissues, and muscles out of the way with retractors. Currently, there are two common types of retractors for this purpose—self-retaining retractors, which stay open on their own, and hand-held retractors, which need an assistant to hold them. The current disclosure describes an adapter that couples the hand-held retractors to the self-retaining retractor, enabling the hand-held retractors to be self-retaining. This eliminates the need for an assistant and affords the surgeon better exposure to the bone, thereby increasing the efficiency of surgery while reducing cost. Technology Overview:  The device combines the functions of a hand-held retractor, used on soft tissue near the bone, with those of a self-retaining retractor, used on surface levels like skin and subcutaneous fat. The device consists of two sleeves slipped over the arms of the hand-held retractors. The inner surfaces of the sleeves have inverted V-shaped projections to capture the tips of the self-retaining retractor. When the tips are inserted into the projections on the sleeves, the self-retaining retractor secures the hand-held retractors and keeps them open. The adapter can be used with equipment that is readily available in every orthopedic operating room. It will be made of sterilizable metal or durable plastic to guarantee years of use.   https://suny.technologypublisher.com/files/sites/110-20302.jpg Advantages:

  • Increases efficiency of surgery.
  • Reduces costs.